Endless, I know you are only looking at Neuren from a trader's perspective but, given your pervious comments, hopefully the company has changed your view on ASX biotechs since your post in December 2021:
"Patsy 2 said. "Would love to hear how NEU announcement didn't impress you?"
First thing. I did not say that. I said "recent anncmnt wasn't that amazing."
• Trofinetide met co-primary efficacy endpoints demonstrating statistically significant improvement over placebo in the Rett Syndrome Behaviour Questionnaire (RSBQ) (p=0.0175) and the Clinical Global Impression of Improvement (CGI-I) (p=0.0030)
• Trofinetide met key secondary endpoint demonstrating statistically significant improvement over placebo in CSBS-DP-IT–Social (p=0.0064), caregiver scale of ability to communicate.
Best they can say is that the results were 'encouraging'. This was a small study and only had an affect on the symptoms of Retts, not the disease itself. There were still significant side effects. Based on these results I would not think it that likely that this treatment would get FDA approval. (About same chance as Gladys B not getting found guilty of corrupt behaviour in office).
All the guff about how much $$$s is just speculation based on the drug being commercialised. NEU has been going on about stuff like this for years.
I would love this to be a breakthrough as I know peeps dealing with this disorder.
Trader would have sold near $4. imo
And my comments are in the context of there being virtually zero successful bio-med/bio-tech spec stocks on the ASX EVER!"
- Forums
- ASX - Day Trading
- Morning Trading March 13
Endless, I know you are only looking at Neuren from a trader's...
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online